- Home
- TURN vs OCX Comparison
TURN vs OCX Comparison
Compare TURN & OCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TURN
- OCX
- Stock Information
- Founded
- TURN 1981
- OCX 2009
- Country
- TURN United States
- OCX United States
- Employees
- TURN N/A
- OCX N/A
- Industry
- TURN Finance/Investors Services
- OCX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- TURN Finance
- OCX Health Care
- Exchange
- TURN Nasdaq
- OCX Nasdaq
- Market Cap
- TURN 39.6M
- OCX 80.1M
- IPO Year
- TURN N/A
- OCX N/A
- Fundamental
- Price
- TURN $3.72
- OCX $3.87
- Analyst Decision
- TURN
- OCX Buy
- Analyst Count
- TURN 0
- OCX 3
- Target Price
- TURN N/A
- OCX $4.42
- AVG Volume (30 Days)
- TURN 38.0K
- OCX 120.1K
- Earning Date
- TURN 05-12-2025
- OCX 04-11-2025
- Dividend Yield
- TURN N/A
- OCX N/A
- EPS Growth
- TURN N/A
- OCX N/A
- EPS
- TURN N/A
- OCX N/A
- Revenue
- TURN $194,813.00
- OCX $709,000.00
- Revenue This Year
- TURN N/A
- OCX N/A
- Revenue Next Year
- TURN N/A
- OCX $106.34
- P/E Ratio
- TURN N/A
- OCX N/A
- Revenue Growth
- TURN 254.25
- OCX N/A
- 52 Week Low
- TURN $3.12
- OCX $1.92
- 52 Week High
- TURN $4.40
- OCX $4.75
- Technical
- Relative Strength Index (RSI)
- TURN 36.71
- OCX 71.87
- Support Level
- TURN $3.67
- OCX $3.60
- Resistance Level
- TURN $3.90
- OCX $4.75
- Average True Range (ATR)
- TURN 0.11
- OCX 0.47
- MACD
- TURN -0.03
- OCX 0.10
- Stochastic Oscillator
- TURN 28.26
- OCX 63.77
About TURN 180 Degree Capital Corp.
180 Degree Capital Corp is active in the financial services domain. It is a non-diversified closed-end management investment company whose objective is to achieve long-term capital appreciation by making venture capital investments. It focuses its investments on companies commercializing and integrating products enabled by disruptive technologies mainly in the life sciences, precision medicine, and health industries.
About OCX Oncocyte Corporation
OncoCyte Corp focuses on the discovery, development, and commercialization of novel, non-invasive, liquid biopsy diagnostics for the early detection of cancer. The company develops diagnostic tests based on liquid biopsies using blood or urine samples for detecting lung, bladder, and breast cancers. In addition, it also develops screening diagnostics as potential replacements for screening imaging procedures that do not meet the needs of patients, health care providers or payers.